The U.S. Food and Drug Administration (FDA) has approved Arrowhead Pharmaceuticals, Inc.’s (NASDAQ:ARWR) Redemplo (plozasiran), a small interfering RNA (siRNA) medicine, as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS).
FCS is a rare,…